EGFR and head and neck squamous cell carcinoma: As a proof of concept, the anti-EGFR antibody cetuximab has been shown to improve radiation sensitivity in head and neck squamous cell carcinoma (HNSCC) in multicenter phase III clinical trials [46,47].